BC 3425
Alternative Names: BC-3425Latest Information Update: 14 Feb 2023
At a glance
- Originator Biocity Biopharmaceutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Jan 2023 BC 3425 is available for licensing as of 24 Jan 2023 (Biocity Biopharmaceutical pipeline, January 2023)
- 24 Jan 2023 Phase-I clinical trials in Solid tumours in China (Parenteral) (Biocity Biopharmaceutics pipeline, January 2023)
- 24 Jan 2023 Preclinical trials in Solid tumours in China before January 2023 (Parenteral) (Biocity Biopharmaceutical pipeline, January 2023)